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Abstract
Objective The short-term effect (60 days) of Lactobacillus brevis CD2 lozenges vs placebo on variables related to caries and
gingivitis in type 1 diabetic children was evaluated.
Material and methods Eight diabetics (4–14 years old) were assigned to two groups (n = 34 subjects each), probiotic lozenges
and placebo. Stimulated saliva for microbiological analysis and plaque pHwere assessed at baseline (t0), 30 days (t1), 60 days (t2)
and in the follow-up period (90 days from baseline, t3). Gingival status was assessed at t0, t2 and t3. Two-way ANOVA assessed
differences between groups.
Results In the probiotic group, Streptococcus mutans bacterial density mean scores dropped from 3.11 ± 1.13 at baseline to
1.82 ± 0.72 (t2) and to 2.06 ± 0.56 (t3), while in the placebo group, the scores were 3.09 ± 0.8 (t0), 2.82 ± 0.47 (t2) and 3.11
± 0.43 (t3) (p < 0.01). Lowest and maximum pH fall increased in the probiotic group, from 5.37 ± 0.41 at baseline to 5.49 ±
0.24 at t3 (p < 0.01) and from 1.20 ± 0.46 to 0.98 ± 0.29 (p = 0.02). Bleeding score decreased significantly in both groups,
showing a statistically significant lower bleeding score at t2 in the probiotic group (25.6%, 95% CI 21.5–32.7 vs 29.5%,
95% CI 25.2–34.9, p = 0.02).
Conclusions Lactobacillus brevis CD2 has shown to improve caries-related risk factors and gingival health in diabetic children.
Clinical relevance Lactobacillus brevis CD2 might contribute to improved oral health in type 1 diabetic children.
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Introduction
Diabetes mellitus is a chronic disease resulting from a relative
or absolute deficiency of insulin, which affects themetabolism
of carbohydrate, protein and fat [1]. Commonly occurring
complications are nephropathy, dyslipidaemia, neuropathy,
and retinopathy [2]. Sardinia (Italy) together with Finland
and Sweden are known to have the highest incidence of type
1 diabetes in the world [1, 3–6].
Diabetic patients do often show high prevalence of
gingivitis, periodontal disease and xerostomia, and these
comorbidities can be correlated with the disease dura-
tion and degree of the metabolic control [7]. Changes in
the oral microflora of diabetic subjects in relation to
poor glycaemic control may significantly influence the
prevalence of gingivitis and caries [7–10]. An associa-
tion between diabetes and dental caries has been postu-
lated. Unbalanced diabetes (HbA1c < 7.5%-58
mmol/mol) [10–12] is associated with significant cario-
genic changes in the oral environment, including less
resting and stimulated whole saliva, lower saliva buffer-
ing capacity and pH, higher salivary glucose and albu-
min concentrations, higher proportion of salivary mutans
streptococci and yeast [12, 13]. Recently, it was dem-
onstrated that diabetic children in good metabolic con-
trol are considered at low caries risk, while those in bad
metabolic control showed an oral environment prone to
caries development [10].
Different strategies, including the use of probiotic
strains, have been suggested in order to prevent gingivitis
and caries [14–20]. The major drawback of the use of
probiotic for oral health is that the majority of probiotics
used are not oral bacteria and so a daily administration is
needed to maintain the positive effect [15]. In different
fields of oral health care, probiotics have demonstrated a
clinical effect on different oral conditions such as halito-
sis, oral candidiasis and dental caries [17–20]. The use of
probiotics in caries prevention leads to the inhibition of
the prol i ferat ion of car iogenic bacter ia (mainly
Streptococcus mutans) and the reduction of bacteria ad-
herence to the tooth surfaces. The effect of different
strains of probiotics has been evaluated, obtaining a reduc-
tion in caries incidence, a reduced concentration of mutans
streptococci and lactobacilli in plaque and saliva, a de-
creased plaque acidogenicity and a reversal of root caries
lesions [11, 16, 18–24].
The hypothesis behind this randomised clinical trial (RCT)
was that the administration of probiotic lozenges containing
Lactobacillus brevis CD2 will be able to modify the oral mi-
croflora composition, biofilm acidogenicity and gingival
health in children diagnosed at least 2 years before with type
1 diabetes. The null hypothesis was that the probiotic strain
would not modify the oral health-related variables.
Material and methods
Study design and sample
The study protocol was approved by the Ethical Committee of
the University of Sassari [protocol number 133/2014] and
conducted according to the principles of the Helsinki
Declaration II (ClinicalTrials.gov Identifier: NCT01778699)
The study was carried out in the Dental Clinic of the
University of Sassari, School of Dentistry, Sassari (Italy) and
lasted from May 2016 to March 2017.
The inclusion criteria were (1) age between 4 and 14 years,
(2) type 1 diabetes diagnosed at least 2 years before, (3) good
general health except for diabetes and (4) reported to clean the
teeth at least twice a day. Exclusion criteria were (1) ongoing
oral/dental treatment except for emergency treatment, (2)
presence of the oral mucosa diseases, (3) use of fluoride-
containing products except for toothpaste within the 14 days
from the beginning of the trial, and (4) antibiotic therapy with-
in the past 6 months.
A sample size calculation was performed before the start of
the trial using the web-based OpenepiTM platform (http://
openinfo.com), considering a difference between the two
groups of 5% regarding probiotic effects on oral health in
children [16, 17, 25]. The bilateral significance level was set
at 95% with a power of 80%. The number of diabetic children
needed to be enrolled was fixed in 64. Information on the
study aim and design was mailed to 75 parents of children
with type I diabetes treated at the Paediatric Clinic of the
University of Sassari (Italy), asking the consent for their
child participation into the study. Seventy-two diabetic chil-
dren agreed to participate and 68 were enrolled. HbA1c levels
were obtained from their medical charts.
Randomisation was carried out on an individual basis by
FC using Excel® 2010 for Mac and two groups of 34 children
each were created: (1) a probiotic group, using non-sucrose
lozenges containing Lactobacillus brevis CD2 and (2) a con-
trol group, using non-sucrose lozenges with no active ingre-
dients. The flowchart of the study design is reported in Fig. 1.
One week before the start of the experiment, all the subjects
began to use a 1400-μg/g AmF toothpaste (Gaba-Colgate,
Rome), for daily oral hygiene. A soft toothbrush was likewise
provided, and they were asked to avoid any other oral hygiene
adjuvant.
Treatment
The probiotic lozenges (Inersan®, CD Investments srl, Rome,
Italy) contained 2,000,000,000 colonies of Lactobacillus
brevis CD2, sweeteners (mannitol, aspartame, fructose), anti-
caking agents (talc, silicon dioxide, magnesium stearate) and
banana flavouring. The lozenges for the control group
contained exactly the same ingredients, except for the
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L. brevis CD2. The two lozenges were identical in weight (1
g), form, colour and packing and they were coded as either
“green” or “red”. The code was sealed by an independent
monitor and was not broken until the statistical analysis was
finalised. Each subject took two lozenges a day, one in the
morning and one in the evening, during the whole experimen-
tal period (60 days). The compliance and any observed side
effects of the products were assessed by means of a question-
naire administered to the participants’ parents at day 60 (t2).
Children were instructed to slowly dissolve the lozenges be-
fore swallowing them and to refrain to eat or drink for at least
30 min after exposure.
Clinical examination, saliva sampling and pH
measurement
All subjects were instructed not to brush their teeth or to eat/
drink during the hour before the oral examination.
The clinical examination was made under optimal lighting
using a mirror and a World-Health-Organization probe to as-
sess caries lesions and gingival conditions. The WHO probe
has a coloured band (called the reference marking) located
3.5–5.5 mm from the probe tip. Caries registration was
realised at baseline using the International Caries Detection
and Assessment System (ICDAS) [25]. No radiographs for
caries diagnosis were used [22]. Furthermore, the bleeding
on probing score for all teeth was assessed at baseline (t0), at
the end of the treatment (t2) and in the follow-up period (t3).
Data on their medical condition was also retrieved from their
medical charts.
Saliva sample was collected during 5 min of continuously
spitting into a test tube after 60 sec of pre-stimulation using
paraffin gum [26, 27]. Younger children were instructed on
the collection procedure and followed during the test,
instructing them repeatedly to spit during the entire procedure
time.
Immediately after the saliva sampling, plaque
acidogenicity was assessed using the pH indicator strips in 2
maxillary interproximal spaces: (1) between the first and the
second right and left primary molars in the younger children
or (2) between the 2nd primary and 1st permanent right and
left molars in the older children. Measurements were per-
formed before (0 min) and at 2, 5, 10, 15, 20 and 30 min after
a mouth rinse with 10% sucrose solution for 1 min. The strips
measure a pH value in the range of 4.0–7.0 (Spezialindikator,
pH range 4.0–7.0; Merck, Darmstadt, Germany) [27–29].
Each strip was cut into 4 pieces (approx. 2 mm in width) to
get a strip that more easily could be inserted into the interprox-
imal space. The strip was held in situ for 10 s after which it
was removed, and its colour was compared to the colour index
scheme supplied by the manufacturer. The pHwas determined
to one decimal of the value. For each site, 3 measurements
were carried out at each time point [30, 31]. A Stephan curve
was generated for each participant at each visit, with three
parameters derived from the curve, namely, the lowest pH
reached, the maximum pH fall and the AUC below the enamel
critical pH (5.5).
Fig. 1 Flow chart of the study
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Microbiological analyses
The saliva samples were sent to the Department of
Microbiology, University of Sassari for the evaluation of oral
microflora [32].
The microbiological analysis was made using the checker-
board DNA-DNA hybridisation method [28]. Whole genomic
probes were matched from 9 bacterial strains grouped in pri-
mary cariogenic bacteria (Streptococcus mutans ,
Streptococcus sobrinus , Lactobacil lus casei and
Lactobacillus fermentum) and bacteria known not to be pri-
mary associated with caries (Streptococcus mitis ,
Streptococcus gordoni , Lactobacil lus sal ivarius ,
Streptococcus sanguinis and Streptococcus salivarius).
Matching the obtained signals with the ones generated by
the pooled standard samples, containing a count of 105 and
106 of each bacterial species respectively, an evaluation of the
bacterial count was performed in the samples [27].
Statistical analyses
All the data were input into a spreadsheet (Microsoft Excel1
2011 for Mac, version 14.4.3). Statistical analyses were per-
formed using Stata/SE1 software, version 13.1 forMac (64-bit
Intel). All inputs in the electronic data file were double-
checked (data were entered and analysed twice) and then the
results were compared.
Caries data were grouped as follows: healthy/caries-free
(ICDAS 0), initial (caries in enamel ICDAS 1–2), moderate
(caries not cavitated, ICDAS 3–4) and severe (cavitated caries
in dentin, ICDAS 5–6). The bleeding score, as the percentage
of periodontal sites bleeding on probing, was calculated.
Data from the microbiological analysis was coded on a
scale from 0 to 5: 0 = no signal; 1 = a signal density weaker
than that of the low standard (< 105 bacteria); 2 = a signal
density equal to that of the low standard (= 105 bacteria); 3 = a
signal density higher than that of the low standard but lower
than that of the high standard (> 105 but < 106 bacteria); 4 = a
signal density equal to that of the high standard (= 106 bacte-
ria) and 5 = a signal density higher than that of the high
standard (> 106 bacteria).
The mean plaque pH (± standard error) for all subjects
measured in the two interproximal sites at the different time
points was calculated. The lowest pH value and the maximum
pH fall (difference in pH units between baseline and lowest
pH) after the sucrose rinse were calculated for each subject.
Comparisons of the different variables were made between
the diabetic subjects treated with lozenges containing
Lactobacillus brevis CD2 and diabetic subjects treated with
placebo. All data was analysed univariately to describe the
variables and distributions. To avoid the attenuating effect of
unequal variability between groups on the value of t, a square
root transformation was performed when the response
variable was a count. One-way analysis of variance
(ANOVA) was performed for means comparison between
the two groups [33]. For assessment of the difference between
being in the intervention group or in the control group, mixed-
model analysis for repeated measurements was performed. To
achieve comparable conditions between groups, the variables
gender (factor), microbiological data and plaque pH
(covariate) and Hb1Ac as measured by the TTMC (factor,
attempts until success) were also included in the models.
Fitting of the models was checked graphically by plotting of
the residuals. p < 0.05 was considered statistically significant.
Results
There were no reports of any side effects in the probiotic and
in the control groups. Only one child belonging to the probi-
otic group reported having forgotten a single lozenge intake.
Caries data are reported in Table 1. No statistically signif-
icant differences were observed in the two groups: the major-
ity of the subjects were caries-free and a restricted minority
had severe caries lesions.
Table 2 shows the microbiological results in the two groups
recorded at baseline, after 30 (t1) and 60 days (t2) of lozenges’
use and 30 days after the cessation of use (day 90, t3). In the
probiotic group, both primary and not primary cariogenic bac-
teria decreased during the experimental period, except for
Lactobacillus salivarius, whose concentration did not under-
go significant changes; Streptococcus mutans concentration
showed the greatest reduction dropped from 3.11 ± 1.13 at
baseline to 1.82 ± 0.72 at t2 and to 2.06 ± 0.56 at t3, respec-
tively (p < 0.01). None significant change was noted for the
concentration of any bacterial species in the control group
during the experimental period. The comparison between
groups shows statistically significant differences between at
30, 60 and 90 days. At the end of the treatment period (t2), all
bacterial species were statistically significant different when
comparing the two groups, with Streptococcus mutans and
Lactobacillus casei showing the highest differences (1.82 ±
0.72 vs 2.82 ± 0.47 for S. mutans and 1.65 ± 0.60 vs 2.22 ±
Table 1 Caries status (ICDAS index) in diabetic subjects, the children
using lozenges with Lactobacillus brevis CD2 (probiotic group) and
lozenges without probiotic bacteria (control group) after randomization
Caries status Probiotic group
% (n)
Control group
% (n)
p value
Caries free (ICDAS 0) 61.9 (21) 55.9 (19) NS
Initial caries (ICDAS 1-2) 17.6 (6) 23.5 (8) NS
Moderate caries (ICDAS 3-4) 17.6 (6) 14.7 (5) NS
Severe caries (ICDAS 5-6) 2.9 (1) 5.9 (2) NS
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0.47 for Lactobacillus casei, p < 0.01 for both). This differ-
ence, although reduced, was also recorded at t1 and t3 for
Streptococcus mutans, Streptococcus sobrinus and
Streptococcus sanguis, only at t1 for Lactobacillus casei and
Lactobacillus salivarius and only at t3 for Streptococcus
salivarius.
Table 3 shows the plaque pH measurements expressed as
the lowest pH reached and the maximum pH fall in the two
groups recorded at t0, t1, t2 and t3. Both parameters increased
significantly in the probiotic group: lowest pH changed from
5.37 ± 0.41 at baseline to 5.49 ± 0.24 at t3 (p < 0.01) and
maximum pH fall from 1.20 ± 0.46 to 0.98 ± 0.29 (p = 0.02)
in the same interval. No significant differences were recorded
for both pH parameters in the control group. Regarding com-
parison between groups, only the lowest pH differed in a sta-
tistically significant way at the end of the lozenges’ use,
reaching the value of 5.69 ± 0.29 in the probiotic group vs
5.48 ± 0.40 in the control group (p = 0.04). Maximum pH fall
did not differ between the two groups in any evaluation.
A statistically significant decrease of the bleeding score
was recorded in both groups from baseline to the last follow-
up examination, even if it was more pronounced in the probi-
otic group p = 0.03 in the control group and p < 0.01 in the
probiotic group (Table 4). In the comparison between groups,
subjects using the probiotic lozenges showed a statistically
significant lower bleeding score at the end of the treatment
period (t2, 60 days) compared to the control group (25.6 vs
29.5, p = 0.02). This difference was no more evident 30 days
after the cessation of the lozenges’ administration (32.6 vs
31.9).
The multivariate model showed a statistically significant (p
< 0.01) association between the probiotic administration (de-
pendent variable), the concentration of primary cariogenic
bacteria, the lowest pH, and the bleeding scores. The estimates
for these independent variables were comparable, showing
there were only small differences between groups (Table 5).
Discussion
The goal of this RCT was to evaluate the effect of
Lactobacillus brevis CD2 administered through lozenges
compared to a placebo in a sample of diabetic children diag-
nosed at least 2 years before. Results showed that the 60-day
administration of the probiotic strain produces a significant
reduction of cariogenic microorganisms compared to the pla-
cebo. A statistically significant, but meager in absolute value,
difference between groups was also noted in the plaque pH
(lowest pH value) and in the bleeding score at the end of the
administration period.
Although a lower prevalence of caries lesions was recorded
in diabetic group than in non-diabetic population at the onset
of the disease, a higher caries prevalence has previously beenTa
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found in diabetic subjects with bad metabolic control com-
pared to diabetic subjects with good metabolic control [10,
12]. These datamight be linked to a more cariogenicmicrobial
flora and consequent lower plaque pH values due to the higher
sugared snack and beverage intake as well as leakage of glu-
cose from the gingival crevicular flow in the non-stabilized
metabolic subjects [7, 9, 10]. Cariogenic bacteria reached a
higher saliva concentration (Streptococcus mutans and
Streptococcus sobrinus) in diabetic children compared to
non-diabetic children, and this concentration was even higher
when a comparison between diabetic children in bad metabol-
ic control vs non-diabetic children was performed [10].
Salivary mutans streptococci concentration was statistically
significant associated to caries experience in diabetic children
[12].
The main result of the present RCT was that the use of
the Lactobacillus brevis CD2 lozenges statistically signif-
icantly affects the salivary concentration of the considered
primary cariogenic bacteria compared to placebo use. The
concentration of Streptococcus mutans and Streptococcus
sobrinus decreased during the use of the probiotic loz-
enge, reaching the highest decrement at the end of the
probiotic administration period. Noteworthy, 30 days after
the cessation of probiotic use, the concentration was still
statistically significant lower compared to control group.
Scientific literature reports heterogeneous results on the
effect of probiotics on Lactobacillus spp. [18]. In the pres-
ent RCT, the concentration of Lactobacillus spp. i.e.
Lactobacillus casei and Lactobacillus fermentum de-
creased during the experimental period, but it increased
again after the cessation of probiotic’s use, underlining
the importance of the continuous administration of the
probiotic to produce a lasting effect, as widely reported
in literature [17–24].
Plaque pH parameters are used for the evaluation of
food cariogenicity and/or individual caries risk assessment
[28–31]. A more acidogenic oral environment has previ-
ously been demonstrated in diabetic children compared to
non-diabetics [10].
It has previously been demonstrated that, Lactobacillus
brevis CD2 lead to a lower plaque acidogenicity compared
to a placebo in high caries-risk children [20]. A certain number
of probiotics showed to be able to produce bacteriocins or
similar substances and usually the effect is pH dependent.
Lactobacillus brevis CD2 is a functional Lactobacillus strain
with peculiar biochemical features, essentially related to the
activity of arginine deiminase [31]. This enzyme catalyses
arginine and affects the biosynthesis of polyamines (putres-
cine, spermidine, and spermine). Findings of the present study
confirm previous results, showing that both the lowest pH and
the maximum pH fall were significantly affected by the pro-
biotic use. Nevertheless, the comparison between the two
groups showed a statistically significant difference at the end
of the administration period (t2) for the lowest pH only,
underlining the slight pH modification produced by the treat-
ment. It is possible to speculate that the duration of the inter-
vention is directly linked to the modification of plaque pH [11,
19, 20]. The pH strip method used showed to be comparable
with the micro-touch method [30, 31] taking into consider-
ation that both methods measure pH only on the plaque
Table 4 Bleeding scores in the
two groups, recorded at baseline
(t0), at the end of the lozenges
administration (t2) and 30 days
after (t3)
Bleeding scores Probiotic group
% (95% CI)
Control group
% (95% CI)
p-value
Baseline (t0) 34.5 (27.8–42.3) 33.4 (27.0–39.6) NS
60 days (t2) 25.6 (21.5–32.7) 29.5 (25.2–34.9) 0.02
90 days (t3) 32.6 (24.6–32.7) 31.9 (23.8–36.0) NS
p value (one-way ANOVA) < 0.01 0.03
Table 3 Plaque pH measurements in the two groups, recorded before (at baseline) and after 30 and 60 days of the lozenges use and 30 days after the
cessation of use
Lowest pH Maximum pH fall
Probiotic group Control group p value Probiotic group Control group p value
Baseline (t0) 5.37 ± 0.41 5.34 ± 0.50 NS 1.20 ± 0.46 1.18 ± 0.56 NS
30 days (t1) 5.46 ± 0.37 5.42 ± 0.44 NS 1.10 ± 0.42 1.13 ± 0.51 NS
60 days (t2) 5.69 ± 0.29 5.48 ± 0.40 0.04 1.02 ± 0.35 1.06 ± 0.45 NS
90 days (t3) 5.49 ± 0.24 5.43 ± 0.43 NS 0.98 ± 0.29 1.07 ± 0.51 NS
One-way ANOVA p value < 0.01 NS 0.02 NS
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surface and in the inter-proximal dental space rather than in
the depth of the dental plaque.
The change in the concentration of primary cariogenic bac-
teria may explain the change in the plaque pH values. The
change of the pH values recorded, even if moderate, is ade-
quate to reduce the caries risk and it is similar to the modifi-
cation reported in literature [15, 19, 20]. Otherwise, some
results about plaque pH would require more investigation
i.e. the maximum pH fall at t1 and t2 recorded in the control
group. One hypothesis could be that children in the control
group respond to a placebo effect as a slight improvement in
plaque pH is found as they were using a lozenge resulting in
increased salivary secretion rate and thereby positive salivary
effects during the study period.
An important parameter associated to gingival health,
the bleeding score, was also evaluated. A reduction in gin-
gival bleeding was found during the trial in both groups,
but a statistically significant difference between groups
was found only at the end of the probiotic administration.
The improvement in the bleeding score in the control
group might be related to the behaviour modification of
the subjects enrolled into a trial, producing a bias in the
study results and reducing the differences between groups.
An anti-inflammatory effect of Lactobacillus brevis CD2
administered to a group of patients with chronic periodon-
titis was reported and related to the capacity of the probi-
otic to prevent the production of nitric oxide and, conse-
quently, the release of PGE2 and the activation of MMPs
induced by the nitric oxide [34].
The optimal dose of probiotic strains for caries prevention
is yet to be clarified. From an analysis of the literature, a huge
interval ranged between 107 and 109 bacteria is reported [35,
36]. This RCT used a quite high dose (four billion of colonies/
die), which is high enough to expect some kind of effect. It
seems likely that probiotic lactobacilli, like Lactobacillus
brevis CD2, might have played an antagonistic effect on car-
iogenic bacteria i.e. Streptococcus mutans and sobrinus in
plaque biofilm.
Some limits of the study design need to be underlined. First
of all, the characteristics of the study population, children
affected by type I diabetes, do not allow to generalise the
results to the general diabetic population, including adults,
taking into consideration that the majority of studies were
carried out on adults. Although claimed that all subjects
followed the instructions given, it may still be questioned
whether this holds for children at all ages. Furthermore, no
analyses have been made in relation to years since disease
onset, but it cannot be excluded that this is a factor that may
influence the findings.
Another limitation might be the variation of plaque pH and
bleeding scores in the control group leading to a minimisation
of the differences between groups. This might be linked to a
“trial-effect bias” as all the subjects received oral hygiene
instruction at the enrolment.
Although several studies were carried out on the caries
preventive effect of probiotic [37, 38], this study holds
almost unique characteristics like the type of the subjects
enrolled (type 1 diabetics) and the age of subjects (4–14
years of age), as well as the probiotic used, known to play
an important role in oral health. The administration of
probiotics with these potentially beneficial properties may
be a viable approach to maintain or restore a healthy bal-
ance in the microbiota. It has recently been shown that type
1 diabetes at early age debut may have a large impact on
general health, including cardiovascular diseases and even
mortality [4]. It is believed that this, due to the disease
complexity, holds also for oral health.
In conclusion, the 60-day administration of the probiotic
strain Lactobacillus brevis CD2 through lozenges is able to
have a positive effect on important variables related to oral
health in diabetic children even if the strength of the effect
might be questionable. A reduction of cariogenic microorgan-
isms’ concentration, plaque pH scores and bleeding on prob-
ing was recorded. This study provides evidence in favour of
the use of Lactobacillus brevis CD2 as a promising functional
food option to improve oral health in diabetics. Probiotics may
be considered a promising adjunct to the current caries man-
agement procedures such as fluoridation and modification of
dietary sugar intake.
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